Oxford Pharmascience

“Using the integrated gastric model to assess gastric damage has been very valuable to our research and development pipeline.

Our interest has been in assessing the affect of our formulations on the epithelia in relevant Gl secretions with a mucus barrier present.

This has been very useful to us.”

Ann Taylor-Hutchinson, Pharmaceutical Development Director